An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial | Trials | Full Text

An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial | Trials | Full Text

An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial

Primary objective: To determine the efficacy of a candidate antiviral on time to virological cure compared to standard of care within 14 days of randomisation

Authors:James H. McMahon, Jillian S. Y. Lau, Janine Roney, Benjamin A. Rogers, Jason Trubiano, Joseph Sasadeusz, James S. Molton, Bradley Gardiner, Sue J. Lee, Jennifer F. Hoy, Allen Cheng and Anton Y. Peleg

Citation:Trials 2020 21:847

Content type:Letter

 

Published on: 13 October 2020

• ViewFull Text
 
• ViewPDF